Europe needs a nuanced and flexible approach to extract the full potential AI holds for extending coverage, improving diagnoses and increasing staff productivity in healthcare
The EU needs an ambitious and coherent agenda for the 2019-2024 legislative term to boost the resilience, equitability and sustainability of Europe’s healthcare systems. This report, based on a Science|Business expert roundtable, sets out recommendations for such an agenda.
During the 2014-16 Ebola outbreak in western Africa, public health expert Nicolas Meda of Burkina Faso played a key role in his country’s response to the epidemic. In an interview, he sets out the lessons learnt from the experience.
Science|Business is canvassing views on the big research priorities for the next term of the EU, from 2019 to 2024. Here, six policy experts discuss the most pressing items on the EU’s to-do list for health
New report shows how long term investment in novel products like cell and gene therapies is beginning to bear fruit. The concern now is the price of these products and ensuring patients get access
Advanced therapies feature in new Innovative Medicines Initiative Calls for proposals, along with topics on artificial intelligence; the need for reliable, relevant health information; and ways of incorporating patients’ perspectives into healthcare and cancer clinical trials.
In medical image analysis, AI can surpass human experts; in diabetes it can raise an alarm in time to head off a glycaemic event. Hints of its power, but concerns about privacy are slowing deployment of AI tools
IMI has involved patients in its projects and activities since the beginning. Now, IMI is creating a pool of patient experts to strengthen the role and voice of patients in IMI activities at strategic and operational levels.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.